? Keytruda is a drug indicated for the treatment of skin cancer, also called melanoma, non-small cell lung cancer, bladder cancer and stomach cancer in people whose cancer has spread or cannot be eliminated by surgery.
This drug has pembrolizumab in its composition, which helps the immune system fight cancer and reduce tumor growth.
Keytruda is not available for sale to the public as it is a medicine that can only be used in hospital.
Pembrolizumab is indicated for the treatment of
Keytruda is usually received by people whose cancer has spread or cannot be eliminated by surgery.
The amounts of Keytruda to be used and the duration of treatment depend on the state of the cancer and the individual response of each patient to treatment and should be indicated by the doctor.
Generally, the recommended dose is 200 mg for uothelium cancer, gastric cancer and undated microcytic lung cancer or 2 mg/kg for melanoma or non-microcytic lung cancer with prior treatment.
It is a medicine that should only be administered intravenously for approximately 30 minutes by a qualified doctor, nurse or health care professional, and treatment should be repeated every 3 weeks.
The most common side effects that can occur during treatment with Keytruda are diarrhea, nausea, itching, skin redness, joint pain and fatigue.
In addition, there may also be a reduction in red blood cells, thyroid problems, hot flashes, decreased appetite, headaches, dizziness, changes in taste, inflammation of the lungs, shortness of breath, cough, inflammation of the intestines, dry mouth, headache, stomach pain, constipation, vomiting, muscle pain, bone and joint pain, swelling, fatigue, weakness, chills, flu, increased liver and blood enzymes and reactions at the injection site.
Keytruda should not be used in people allergic to any of the ingredients of the formula, as well as in pregnant or lactating women.